{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:25Z","timestamp":1790155705014,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.cyto.2012.12.011","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T10:47:47Z","timestamp":1358419667000},"page":"933-939","source":"Crossref","is-referenced-by-count":23,"title":["Vascular Endothelial Growth Factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement"],"prefix":"10.1016","volume":"61","author":[{"given":"Anna","family":"Zampetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gnarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Borsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Giurdanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Antuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"de Waure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Feliciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2012.12.011_b0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cyto.2012.12.011_b0010","unstructured":"http:\/\/www.hgmd.cf.ac.uk\/ [accessed 08.12]."},{"key":"10.1016\/j.cyto.2012.12.011_b0015","first-page":"227","article-title":"Fabry disease: twenty two novel mutations in the alpha-galactosidase A gene and genotype \/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Ashton-Prolla","year":"2000","journal-title":"J Invest Med"},{"key":"10.1016\/j.cyto.2012.12.011_b0020","series-title":"The metabolic and molecular bases of inherited disease","article-title":"a-Galactosidase a deficiency: Fabry disease","author":"Desnick","year":"2001"},{"issue":"10","key":"10.1016\/j.cyto.2012.12.011_b0025","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","volume":"35","author":"Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cyto.2012.12.011_b0030","series-title":"Fabry disease: perspectives from 5 years of FOS","article-title":"Natural history of Fabry disease","author":"Mehta","year":"2006"},{"key":"10.1016\/j.cyto.2012.12.011_b0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0040","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2133.2012.10742.x","article-title":"Angiokeratoma: decision-making aid for the diagnosis of Fabry disease","volume":"166","author":"Zampetti","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.cyto.2012.12.011_b0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0050","first-page":"314","article-title":"Fabry-Anderson disease: current state of knowledge","volume":"63","author":"Vega-Vega","year":"2001","journal-title":"Rev Invest Clin"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Int Med"},{"issue":"7","key":"10.1016\/j.cyto.2012.12.011_b0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.cyto.2012.12.011_b0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.carpath.2009.10.003","article-title":"The heart in Fabry\u2019s disease","volume":"20","author":"Sheppard","year":"2011","journal-title":"Cardiovasc Pathol"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0075","first-page":"823","article-title":"Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease","volume":"2","author":"Fervenza","year":"2008","journal-title":"Biologics"},{"issue":"9","key":"10.1016\/j.cyto.2012.12.011_b0080","first-page":"561","article-title":"Update on the treatment of Fabry\u2019s disease: pathophysiological concepts","volume":"51","author":"Politei","year":"2010","journal-title":"Rev Neurol"},{"key":"10.1016\/j.cyto.2012.12.011_b0085","first-page":"69","article-title":"Enzyme replacement therapy for Fabry disease: some answers but more questions","volume":"7","author":"Alfadhel","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cyto.2012.12.011_b0090","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.cyto.2012.12.011_b0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0100","doi-asserted-by":"crossref","first-page":"e36373","DOI":"10.1371\/journal.pone.0036373","article-title":"Globotriaosylsphingosine accumulation and not alpha-galactosidase \u2013 A deficiency causes endothelial dysfunction in Fabry disease","volume":"7","author":"Namdar","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1399-0004.2011.01689.x","article-title":"Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene","volume":"81","author":"Ferri","year":"2012","journal-title":"Clin Genet"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0110","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.cyto.2012.12.011_b0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cyto.2012.12.011_b0120","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.cyto.2012.12.011_b0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2011.01.003","article-title":"Interpretation of elevated serum VEGF concentrations in patients with myocardial infarction","volume":"54","author":"Korybalska","year":"2011","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cyto.2012.12.011_b0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.STR.32.1.275-b","article-title":"Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke","volume":"32","author":"Gunsilius","year":"2001","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.cyto.2012.12.011_b0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2133.2011.10204.x","article-title":"Infantile haemangioma: new aspects on the pathogenesis of the most common skin tumour in children","volume":"164","author":"Hoeger","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cyto.2012.12.011_b0140","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.cyto.2012.12.011_b0150","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0891-5849(02)01005-5","article-title":"Redox signaling in vascular angiogenesis","volume":"33","author":"Maulik","year":"2002","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10.1016\/j.cyto.2012.12.011_b0155","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00417-011-1682-0","article-title":"Lysosomal stress and lipid peroxidation products induce VEGF-121 and VEGF-165 expression in ARPE-19 cells","volume":"249","author":"Bergmann","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.cyto.2012.12.011_b0165","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1073\/pnas.0611315104","article-title":"Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities","volume":"104","author":"Moore","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.cyto.2012.12.011_b0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.cyto.2012.12.011_b0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1479164111426162","article-title":"Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients","volume":"9","author":"Bleda","year":"2012","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0180","first-page":"271","article-title":"An association study of inflammatory cytokine gene polymorphisms in Fabry disease","volume":"17","author":"Safyan","year":"2006","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2230.2008.03104.x","article-title":"Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence","volume":"34","author":"Man","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1016\/j.cyto.2012.12.011_b0190","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1359\/jbmr.090602","article-title":"Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF","volume":"24","author":"Schipani","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.cyto.2012.12.011_b0195","first-page":"559","article-title":"Role of angiogenesis on bone formation","volume":"27","author":"Portal-N\u00fa\u00f1ez","year":"2012","journal-title":"Histol Histopathol"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jdermsci.2010.03.023","article-title":"Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis \u2013 a possible target for novel therapies?","volume":"58","author":"Canavese","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.cyto.2012.12.011_b0205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2133.2011.10204.x","article-title":"Infantile haemangioma: new aspects on the pathogenesis of the most common skin tumour in children","volume":"164","author":"Hoeger","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.cyto.2012.12.011_b0210","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.bone.2009.11.015","article-title":"Plasma VEGF determination in disseminated lymphangiomatosis\u2013Gorham\u2013Stout syndrome: a marker of activity? A case report with a 5-year follow-up","volume":"46","author":"Dupond","year":"2010","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.cyto.2012.12.011_b0215","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bjo.2009.176651","article-title":"Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity","volume":"94","author":"Allen","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.cyto.2012.12.011_b0220","unstructured":"G. Stifano, L. Montrone, B. Falsini et al. Assessment of Macular Function in Fabry\u2019s Disease Patients With No or Minimal Evidence of Retinal Involvement Association for Research in Vision and Ophthalmology (ARVO) April 27\u2013May 1 2008; Fort Lauderdale, Florida, USA. poster presentation."},{"issue":"5","key":"10.1016\/j.cyto.2012.12.011_b0225","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1755-3768.2010.02079.x","article-title":"Treatment of proliferative diabetic retinopathy with anti-VEGF agents","volume":"89","author":"Salam","year":"2011","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.cyto.2012.12.011_b0230","doi-asserted-by":"crossref","first-page":"F1026","DOI":"10.1152\/ajprenal.00410.2011","article-title":"VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice","volume":"303","author":"Oltean","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.cyto.2012.12.011_b0235","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int J Mol Med"},{"issue":"12","key":"10.1016\/j.cyto.2012.12.011_b0240","first-page":"1666","volume":"61","author":"Dei Cas","year":"2012","journal-title":"VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment? Metabolism"},{"issue":"10","key":"10.1016\/j.cyto.2012.12.011_b0245","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/jnr.23088","article-title":"Effects of vascular endothelial growth factor in ischemic stroke","volume":"90","author":"Ma","year":"2012","journal-title":"J Neurosci Res"},{"issue":"6","key":"10.1016\/j.cyto.2012.12.011_b0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/01.STR.0000165925.20413.14","article-title":"Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction","volume":"36","author":"Kimura","year":"2005","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.cyto.2012.12.011_b0255","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1161\/STROKEAHA.110.607739","article-title":"Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction","volume":"42","author":"Kim","year":"2011","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.cyto.2012.12.011_b0260","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/157016112800812836","article-title":"Angiogenesis and Hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies","volume":"10","author":"Ferroni","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.cyto.2012.12.011_b0265","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1749-6632.2010.05601.x","article-title":"Cigarette smoke-mediated oxidative stress, shear stress, and endothelial dysfunction: role of VEGFR2","volume":"1203","author":"Edirisinghe","year":"2010","journal-title":"Ann NY Acad Sci"},{"issue":"12","key":"10.1016\/j.cyto.2012.12.011_b0270","doi-asserted-by":"crossref","first-page":"e29055","DOI":"10.1371\/journal.pone.0029055","article-title":"Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes","volume":"6","author":"Leychenko","year":"2011","journal-title":"PLoS One"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466612008216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466612008216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T08:13:43Z","timestamp":1562573623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466612008216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1043466612008216"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2012.12.011","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}